Have you been diagnosed with early stage triple negative breast cancer? We are asking you to take part in this research study because you have been diagnosed with triple-negative breast cancer (TNBC) and have recently completed preoperative chemotherapy in combination with pembrolizumab, followed by breast surgery. The chemotherapy plus pembrolizumab produced a pathologic complete response (pCR), meaning that no remaining cancer was found during your breast surgery.

Have you been diagnosed with breast cancer? If so, you may be able to take part in a research study for the collection of tumor specimens and genomic DNA from patients with early or metastatic breast cancer.

Community-based interventions outside of North Carolina increase prostate cancer risk awareness and education among African Americans. Help us design an ideal intervention for/with communities in North Carolina. Your feedback and insight are instrumental in raising awareness and ultimately saving the lives of Black/African American men in North Carolina.

Do you Patients with have Advanced Nasopharyngeal Carcinoma that has Progressed After Platinum Treatment and Immunotherapy? If so, you may be able to participate in a research study to find out if progression-free survival of the triplet combination (CaboNivoIpi) is more favorable than the doublet (NivoIpi).

The purpose of this study is to find out whether a combination of drugs is a safe treatment for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. The combination of drugs in this study is cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC. In addition, we will find out whether the study drug combination is an effective treatment for these conditions.

Are you a premenopausal woman with hormone-positive breast cancer? If so, you may be able to participate in a study to learn if adding chemotherapy to the usual treatment improves survival and decreases the chances of cancer coming back.

The purpose of this study is to understand what factors encourage and discourage rural and racially and ethnically diverse populations to participate in cancer clinical research studies. The study is focused on people living in Bertie, Hertford, Robseon and Scotland Co, NC and neighboring counties. We also want to hear what healthcare providers in these NC areas think about cancer clinical research barriers and facilitators.

We would like to learn about how people who apply for healthcare financial assistance experience the application process, including things that make the application process work well or that were challenging. At this time we are not able to offer interviews to people who applied to UNC or Duke, we are interested in hearing from people who applied to other programs (such as Atrium, Novant, Wake, Vidant, ECU, Cape Fear Health Net, Physicians Reach Out, or Project Access).

Are you scheduled for or planning to have a biopsy done at UNC Health? For this trial, we are looking for people who are 18 years or older who are suspected or diagnosed with Stage IV/metastatic cancer, including: • Lung: Non-small cell lung cancer (NSCLC), • Head and Neck: Squamous Cell Carcinoma (HSNCC), excluding nasopharyngeal and salivary gland cancer; • Kidney: Clear Cell Renal Cell Carcinoma (ccRCC); • Bladder: Urothelial Carcinoma (UC); Skin: Cutaneous Melanoma, excluding Uveal Melanoma.

Have you been diagnosed with triple negative breast cancer and have residual disease after receiving preoperative therapy and surgery?